Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Efficacy of Melissa Officinalis Plus Mediterranean Diet in Patients With Moderate Rheumatoid Arthritis: A Pilot Clinical Trial Study Protocol Publisher



Alijaniha F1, 2 ; Mizani A1, 3 ; Rostamian A4 ; Movaseghi S4 ; Naseri M1, 2, 5 ; Hajati RJ1 ; Mirsharif ES6 ; Tuserkani F6 ; Najafizadeh SR4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran
  2. 2. Department of Persian Medicine, School of Medicine, Shahed University, Tehran, Iran
  3. 3. Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran
  4. 4. Rheumatology Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Hikmat, Islamic and Traditional Medicine Department, The Academy of Medical Sciences, Tehran, Iran
  6. 6. Immunoregulation Research Center, Shahed University, Tehran, Iran

Source: Advances in Integrative Medicine Published:2025


Abstract

Introduction: Rheumatoid arthritis (RA) as an autoimmune disease is characterized by chronic inflammation, pain, and swelling of diarthrodial joints. Despite progress in RA diagnosis, existing medications have limited effectiveness and should be used cautiously due to their adverse and toxic effects. According to Persian medicine, Melissa officinalis is a good candidate for the treatment of inflammation diseases. This clinical trial will aim to assess the treatment efficacy of M. officinalis and serum concentration of inflammatory biomarkers (TNF-α, IL-17) and also determine the effects of the Mediterranean diet on patients with moderate rheumatoid arthritis. Methods: This randomized, pilot double-blind placebo-controlled clinical trial study will be conducted on 20 eligible patients with moderate RA who will be randomly divided into intervention and placebo groups. The intervention group will use 500 mg of M. officinalis capsule twice a day, and the placebo group will receive 500 mg of bread powder capsule twice daily for 12 weeks. The Disease Activity Score 28-ESR, DAS 28-CRP, Clinical Disease Activity Index and Simplified Disease Activity Index, and also IL17, TNF-α will be assessed at the baseline and end of the trial as primary outcomes in both groups. As a secondary outcome, the World Health Organization Quality of Life-BREF, Depression Inventory–II questionnaire, and International Physical Activity Questionnaires will be used to assess the quality of life of patients and the antidepressant effect of M. officinalis, as well as the role of physical activity in reducing inflammation in RA patients. Kidney and liver parameters will be evaluated at pre- and post-treatment stages. Discussion: Results of this trial are expected to confirm anti-analgesic effects of M. officinalis and its anti-inflammatory agent on serum concentration of inflammatory biomarkers (TNF-α, IL-17) in patients with moderate rheumatoid arthritis. © 2024 Elsevier Ltd
Related Docs
1. Artificial Intelligence in Rheumatoid Arthritis: Current Status and Future Perspectives: A State-Of-The-Art Review, Rheumatology and Therapy (2022)
2. The Effect of a Hydrogel Made by Nigella Sativa L. on Acne Vulgaris: A Randomized Double-Blind Clinical Trial, Phytotherapy Research (2020)
3. The Protective Effect of Melissa Officinalis L. in Visceral Hypersensitivity in Rat Using 2 Models of Acid-Induced Colitis and Stress-Induced Irritable Bowel Syndrome: A Possible Role of Nitric Oxide Pathway, Journal of Neurogastroenterology and Motility (2018)
4. Effects of Melissa Officinalis (Lemon Balm) Consumption on Serum Lipid Profile: A Meta-Analysis of Randomized Controlled Trials, BMC Complementary Medicine and Therapies (2024)
Experts (# of related papers)
View all Related Experts
Roja Rahimi (2)
Arman Zargaran (1)